Harout Semerjian
Chief Executive Officer chez GLYCOMIMETICS, INC.
Fortune : 75 000 $ au 31/03/2024
Profil
Harout Semerjian is the President, Chief Executive Officer & Director at GlycoMimetics, Inc. He was previously the President, Chief Executive Officer & Director at Immunomedics, Inc. for a brief period in 2020.
Before that, he was the Chief Commercial Officer & Executive VP at Ipsen SA from 2018 to 2020 and the Managing Director at Ipsen Pharma SAS.
Semerjian holds an MBA from both Queen's University and Cornell University, as well as an undergraduate degree from Lebanese American University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GLYCOMIMETICS, INC.
0,04% | 15/03/2024 | 25 000 ( 0,04% ) | 75 000 $ | 31/03/2024 |
Postes actifs de Harout Semerjian
| Sociétés | Poste | Début |
|---|---|---|
| GLYCOMIMETICS, INC. | Chief Executive Officer | 06/08/2021 |
Anciens postes connus de Harout Semerjian
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNOMEDICS, INC. | Chief Executive Officer | 27/05/2020 |
| IPSEN | Corporate Officer/Principal | 01/04/2020 |
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | Corporate Officer/Principal | - |
Formation de Harout Semerjian
| Queen's University | Masters Business Admin |
| Cornell University | Masters Business Admin |
| Lebanese American University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| IPSEN | Health Technology |
| GLYCOMIMETICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Ipsen Pharma SAS
Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | Health Technology |
